We are live on ! Find out more
CYAD

Celyad Oncology SA American Depositary Shares
CYAD

Delisted

CYAD was delisted on the 18th of May, 2023.

Back to rankings

8 hedge funds and large institutions have $14.7M invested in Celyad Oncology SA American Depositary Shares in 2019 Q1 according to their latest regulatory filings, with 0 funds opening new positions, 3 increasing their positions, 3 reducing their positions, and 0 closing their positions.

New
Increased
Maintained
Reduced
Closed

7% more capital invested

Capital invested by funds: $13.7M → $14.7M (+$985K)

0% more funds holding

Funds holding: 8 → 8 (0)

0% more repeat investments, than reductions

Existing positions increased: 3 | Existing positions reduced: 3

Holders
8
Holders Change
–
Holders Change %
0%
% of All Funds
0.17%
Holding in Top 10
–
Holding in Top 10 Change
–
Holding in Top 10 Change %
–
% of All Funds
–
New
–
Increased
3
Reduced
3
Closed
–
Calls
–
Puts
–
Net Calls
–
Net Calls Change
–

Top Buyers

Rank Fund Capital Flow
1
Victory Capital Management
Victory Capital Management
Texas
+$556K
2
Morgan Stanley
Morgan Stanley
New York
+$49.2K
3
Wells Fargo
Wells Fargo
California
+$29.7K

Top Sellers

Rank Fund Capital Flow
1
Millennium Management
Millennium Management
New York
-$1.36M
2
UBS Group
UBS Group
Switzerland
-$9.7K
3
TRCT
Tower Research Capital (TRC)
New York
-$1.43K
Name Holding Trade Value Shares
Change 		Change in
Stake
Victory Capital Management
1
Victory Capital Management
Texas
$13.7M +$556K +25,980 +4%
Millennium Management
2
Millennium Management
New York
$554K -$1.36M -63,419 -70%
Morgan Stanley
3
Morgan Stanley
New York
$204K +$49.2K +2,298 +30%
Wells Fargo
4
Wells Fargo
California
$155K +$29.7K +1,390 +22%
UBS Group
5
UBS Group
Switzerland
$17K -$9.7K -453 -34%
Bank of Montreal
6
Bank of Montreal
Ontario, Canada
$2K – – –
Zurich Cantonal Bank
7
Zurich Cantonal Bank
Switzerland
$2K – – –
TRCT
8
Tower Research Capital (TRC)
New York
$1K -$1.43K -67 -63%

CYAD Hedge Fund Activity: Q1 2019 in Review

8 of the 4,620 institutional investors tracked by Wall St. Rank reported a position in Celyad Oncology SA American Depositary Shares (CYAD) for Q1 2019, worth a combined $14.7M — up 7.2% from $13.7M a quarter earlier.

Fund positioning in CYAD was balanced in Q1 2019: 0 funds opened new positions, 0 closed out, 3 added to existing stakes and 3 trimmed.

The largest buyer was Victory Capital Management, adding an estimated $556K. The largest seller was Millennium Management, cutting an estimated $1.36M.

  • 8 institutional investors held Celyad Oncology SA American Depositary Shares (CYAD) as of Q1 2019, unchanged from Q4 2018.
  • Funds reported $14.7M of Celyad Oncology SA American Depositary Shares stock for Q1 2019, up 7.2% quarter-over-quarter.
  • 0 funds opened new Celyad Oncology SA American Depositary Shares positions in Q1 2019 and 0 closed out.
  • The largest Celyad Oncology SA American Depositary Shares buyer in Q1 2019 was Victory Capital Management, an estimated $556K added.
  • The largest Celyad Oncology SA American Depositary Shares seller in Q1 2019 was Millennium Management, an estimated $1.36M sold.

Based on aggregated 13F filings for Q1 2019.